TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20934155
Drug: Continuous irrigation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous irrigation using pH-adjusted lactate Ringer's solution containing tisokinase (96 IU/mL) infused at 20 mL/hr for 48 hours
Study: 20934155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated only with baseline treatment
Study: 12576372
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who maintained their warfarin dose
Study: 12576372
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who decreased their dose by 1 to 20%
Study: 12576372
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who decreased their dose by 21 to 43%
Study: 8542169
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms budesonide (single evening dose)
Study: 8542169
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms budesonide (twice daily for 2 weeks)
Study: 6233335
Drug: Isotretinoin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.1 mg/kg/day
Study: 27164459
Drug: 94 mL
Normalized name: ethanol 0.94 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 94 mL of prewarmed iopromide 240 mg I/mL at 8.3 mL/s
Study: 27164459
Drug: 75 mL
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mL of 300 mg I/mL at 6.7 mL/s
Study: 27164459
Drug: 61 mL
Normalized name: ethanol 0.61 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 61 mL of 370 mg I/mL at 5.4 mL/s
Study: 22523335
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion in the left leg (Study I)
Study: 17660604
Drug: Depakin-chrono, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depakin-chrono, 500 mg tablets, daily dose varied 250-1500 mg/day
Study: 2182578
Drug: Chemotherapy (included
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (included in some trials)
Study: 7000250
Drug: Clindamycin injection
Normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin injection before operation and antibiotic capsules after operation
Study: 7000250
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection and antibiotic capsules
Study: 7000250
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection and placebo capsules
Study: 7000250
Drug: Clindamycin injection
Normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin injection before operation
Study: 7000250
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic injection
Study: 27997703
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine administered on day 1 of chemotherapy (n=43)
Study: 27997703
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine administered on day 11 of chemotherapy (n=54)
Study: 21729116
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride drops orally at a dose of 0.7 mg/kg
Study: 11374408
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g b.i.d.
Study: 11374408
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1-2 mg/kg
Study: 9243683
Drug: Intranasal ketamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine, 3 mg.kg‐1, diluted to 2 ml with saline, 1 ml per naris
Study: 9243683
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal saline, 2 ml, 1 ml per naris)
Study: 2830047
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (1 mg)
Study: 2821784
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 mg)
Study: 2843305
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (10 mg)
Study: 24925006
Drug: Vancomycin for
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin for inhalation (250 mg twice a day)
Study: 23388602
Drug: Cavinton in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton in infusions and then in tablets (cavinton forte)
Study: 23388602
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without cavinton
Study: 17450677
Drug: IL-1 beta
Normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1 beta antagonist (single intraarticular injection of 50 or 150 mg)
Study: 17450677
Drug: IL-1 beta
Normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1 beta antagonist (150 mg)
Study: 17450677
Drug: Anti-TNF alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF alpha therapy
Study: 12755009
Drug: Angiotensin-II receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II receptor blockers
Study: 6331100
Drug: standard aftercare
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard aftercare treatment arrangements (Control group, N = 25)
Study: 30157824
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for neurogenic bladder (NGB) including anticholinergic medications and usual bladder management strategies
Study: 26756747
Drug: Dorzolamide/Timolol Fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/Timolol Fixed Combination (DTFC)
Study: 25175099
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus bevacizumab (150 mg/day erlotinib + 15 mg/kg bevacizumab every 3 weeks)
Study: 25175099
Drug: Erlotinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib alone (150 mg/day)
Study: 21335480
Drug: Pharmacist care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist care program (regular drug-counseling sessions with pharmacists)
Study: 9564798
Drug: High starting
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group A)
Study: 9564798
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of 0.25 mg budesonide twice daily for 1 week (group B)
Study: 2741904
Drug: Mailed self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed self‐administered questionnaire
Study: 31960447
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment containing 5% pyridine-2, 4-dicarboxylic acid diethyl ester and 0.25% resveratrol
Study: 10451911
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 mg
Study: 23052571
Drug: Trazodone 25
Normalized name: trazodone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 25 mg
Study: 16690128
Drug: 0.59-mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.59-mg fluocinolone acetonide implant
Study: 16690128
Drug: 2.1-mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1-mg fluocinolone acetonide implant
Study: 16690128
Drug: 0.59-mg and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.59-mg and 2.1-mg fluocinolone acetonide implants
Study: 16287954
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg/d; n = 4439)
Study: 16287954
Drug: Usual-dose simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual-dose simvastatin (20 mg/d; n = 4449)
Study: 16287954
Drug: Usual-dose simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual-dose simvastatin (20 mg/d)
Study: 12221217
Drug: Milk-based protein
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based protein (MP) 40 g daily for 3 months
Study: 74730
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oestradiol in viscous gel
Study: 74730
Drug: Viscous gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous gel alone
Study: 29891610
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg
Study: 18842612
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (Pw) vs GDoc
Study: 15243470
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg, PILO, n=29)
Study: 15243470
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg, PILO)
Study: 11679972
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon induction therapy (Group A: 10 MU IntronA/day for 2 weeks, then 10 MU/2 days for 12 weeks)
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group B: 5 MU/day for 14 weeks)
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group C: 5 MU/2 days for 14 weeks)
Study: 11679972
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon induction therapy (Group A) in genotype 1 patients
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group B) in genotype 1 patients
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group C) in genotype 1 patients
Study: 11679972
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon induction therapy (Group A) in genotype 3a patients
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group B) in genotype 3a patients
Study: 11679972
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon therapy (Group C) in genotype 3a patients
Study: 9597561
Drug: OROS formulation
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS formulation (75 mg)
Study: 9597561
Drug: IR formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR formulation (75 mg)
Study: 8169026
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream applied for 3 weeks
Study: 25287214
Drug: Ponesimod 100
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod 100 mg
Study: 23597235
Drug: Gardening intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardening intervention including a fruit and vegetable garden, monthly curriculum, gardening support, and technical assistance
Study: 16522412
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice daily until delivery
Study: 12771610
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 40 mg daily
Study: 10695617
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Study: 10695617
Drug: RAC (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC (rabeprazole 20 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Study: 10695617
Drug: R1/2AC (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1/2AC (rabeprazole 10 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Study: 16501426
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus heparin
Study: 3915886
Drug: Tenoxicam (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (continued treatment)
Study: 30265040
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and SUD Using Prolonged Exposure (COPE)
Study: 20435232
Drug: Desirudin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (15 mg SC q12h for patients without thrombosis; 30 mg SC q12h for patients with thrombosis)
Study: 20435232
Drug: Argatroban (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (administered by continuous intravenous infusion according to approved prescribing information or institutional guidelines)
Study: 12452228
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (15 mg/kg intravenously before skin incision and a second bolus of 15 mg/kg at the end of CPB)
Study: 12452228
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (administered at the end of CPB)
Study: 3440095
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of theophylline
Study: 3440095
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of theophylline
Study: 3440095
Drug: Both morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morning and evening dosing of theophylline
Study: 12623326
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of tea catechin extracts (3.7 g/L catechins, 43% epigallocatechin gallate), three times daily for four weeks.
Study: 12623326
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of saline/bromhexine alone (control group).
Study: 12623326
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of tea catechin extracts.
Study: 10874805
Drug: Commercially pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially pure titanium implants
Study: 10874805
Drug: Coated implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated implants
Study: 18261121
Drug: Implant sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant sites
Study: 9169208
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of compounds with conflicting reinforcement histories
Study: 9169208
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of compounds containing some or all novel components
Study: 8249176
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus low-dose MPA (500 mg orally one day/week)
Study: 8249176
Drug: IL-2 alone
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 alone (3 million IU twice/day for 5 days/month subcutaneously)
Study: 8249176
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus low-dose MPA
Study: 28437237
Drug: Hypothermia as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia as adjunctive therapy to PCI
Study: 26256131
Drug: Punica granatum
Normalized name: PUNICA GRANATUM SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punica granatum peel extract (6 g of dry peel/day)
Study: 23899894
Drug: Terbutaline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (8 mg)
Study: 16710647
Drug: Pulsed infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each).
Study: 16710647
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) on the other foot.
Study: 14562491
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (weekly psychoeducation classes focused on nutrition, exercise, and healthy lifestyle)
Study: 10758470
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 2.5 mg followed by PCA bolus 1 mg with a 20‐min lockout (Gp1)
Study: 10758470
Drug: Subcutaneous diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous diamorphine 2.5 mg followed by PCA bolus with a 10‐min lockout period (Gp2)
Study: 10758470
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 2.5 mg in 4 mL of 0.125% (w/v) bupivacaine followed by PCA bolus of 1 mg diamorphine in 4 mL 0.125% (w/v) bupivacaine with a 20‐min lockout (Gp3)
Study: 8642363
Drug: Bodily amplification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bodily amplification and daily life stress interaction at inception
Study: 8642363
Drug: Four-step model
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-step model including bodily amplification, daily life stress, age, and education level
Study: 8642363
Drug: Bodily amplification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bodily amplification and daily irritants interaction at baseline
Study: 20345272
Drug: Steroid-coated (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-coated (triamcinolone acetonide 1%) 18F hydrophilic dilatation catheter for 2 weeks
Study: 17127776
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.2 mg/Kg)
Study: 17127776
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.3 mg/Kg)
Study: 15530132
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of L-T4 tablets (25, 50, 75, 100, 125, 150, 175, 200 microg per tablet; total doses 600, 625 or 700 microg)
Study: 15530132
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of L-T4
Study: 3471936
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (n = 11)
Study: 3471936
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate (n = 7)
Study: 3471936
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (dosages ≤ 40 mg/m2)
Study: 3471936
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (dosages > 40 mg/m2)
Study: 31978697
Drug: Intranasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroids (INS)
Study: 31978697
Drug: Antihistamine (ATH)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (ATH) combined with leukotriene receptor antagonists (LRA)
Study: 31819385
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise (weekly classes and home practice for 20 weeks)
Study: 26102257
Drug: Whole-Body Vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-Body Vibration (WBV) training, twice a week for 8 months
Study: 24858163
Drug: Peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon α‐2a 180μg once weekly plus ribavirin daily for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Study: 19641272
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily for 14 days
Study: 16280696
Drug: EPZ administered
Normalized name: Epzicom
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EPZ administered once daily
Study: 16280696
Drug: ABC +
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABC + 3TC administered twice daily
Study: 2139338
Drug: GR32191B (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191B (80 mg; p.o.)
Study: 2139338
Drug: GR32191B (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191B (40 mg; p.o.)